Antipsychotic drug—Aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms

A Stelmach, K Guzek, A Rożnowska, I Najbar… - Pharmacological …, 2023 - Springer
Second-generation antipsychotics are widely used for the treatment of schizophrenia.
Aripiprazole (ARI) is classified as a third-generation antipsychotic drug with a high affinity for …

Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics

XM Hart, G Gründer, N Ansermot, A Conca… - The World Journal of …, 2024 - Taylor & Francis
Background For psychotic disorders (ie schizophrenia), pharmacotherapy plays a key role in
controlling acute and long-term symptoms. To find the optimal individual dose and dosage …

Understanding inter-individual variability in pharmacokinetics/pharmacodynamics of aripiprazole in children with tic disorders: Individualized administration based on …

Y Xin, L Gao, Y Tuo, G Nie, Y Mei, C Chen… - Frontiers in …, 2022 - frontiersin.org
Objective: This study aims to develop a combined population pharmacokinetic (PPK) model
for aripiprazole (ARI) and its main active metabolite dehydroaripiprazole (DARI) in pediatric …

Pharmacogenetics of praziquantel metabolism: evaluating the cytochrome P450 genes of Zimbabwean patients during a schistosomiasis treatment

G Zdesenko, T Mduluza, F Mutapi - Frontiers in genetics, 2022 - frontiersin.org
Schistosomiasis is a parasitic disease infecting over 236 million people annually, with the
majority affected residing on the African continent. Control of this disease is reliant on the …

[HTML][HTML] Treatment of overthinking: a multidisciplinary approach to rumination and obsession spectrum

A Flaherty, D Katz, A Chosak… - The Journal of …, 2022 - legacy.psychiatrist.com
Classic psychiatry patients are rare; real-world patients tend to have overlapping features of
multiple disorders. Striving for diagnostic certainty, and treatments aimed at tentative …

Effect of CYP2D6 and ABCB1 polymorphisms on pharmacokinetics and efficacy of aripiprazole in pediatric tic disorders

Y Xin, L Gao, S Li, J Wang, C Chen, Y Tuo, G Nie, R Li… - 2024 - researchsquare.com
Backgrounds: Aripiprazole (ARI) is the first-line treatment for tic disorders (TD). It is
metabolized by cytochrome P450 (CYP) 2D6 (CYP2D6) and ATP‐binding cassette, sub …